<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01078623</url>
  </required_header>
  <id_info>
    <org_study_id>M/40464/26</org_study_id>
    <nct_id>NCT01078623</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate</brief_title>
  <acronym>ALIGHT-COPD</acronym>
  <official_title>Efficacy, Safety and Tolerability of Two Fixed-Dose Combinations of Aclidinium Bromide With Two Doses of Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo All Administered Twice Daily in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this multicenter, dose-ranging study is to compare two Fixed-Dose Combinations
      of aclidinium bromide and formoterol fumarate with placebo, aclidinium bromide and formoterol
      fumarate, all administered BID in patients with stable, moderate to severe COPD.

      Every treatment period is 14-days long and there is a 7-days wash-out period in between them.
      The trial starts with a run in phase of 10 to 17-days duration and it ends up with a follow
      up contact 14-days after last treatment dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Normalized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) After Morning Study Drug Administration at Day 14</measure>
    <time_frame>0 and 30 minutes and 1, 2, 3, 4, 6, 8, 10 and 12 hours post-morning dose at Day 14</time_frame>
    <description>FEV1 was measured via spirometry: 2 sets of tests prior to morning dose separated by 30 minutes, and then 1 set at 30 minutes, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-morning dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning Pre-dose FEV1 at Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>FEV1 was measured via spirometry: 2 sets of tests prior to morning dose separated by 30 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning Peak FEV1 at Day 14</measure>
    <time_frame>0 and 30 minutes and 1, 2, 3, 4, 6, 8, 10 and 12 hours post-morning dose at Day 14</time_frame>
    <description>FEV1 was measured via spirometry: 2 sets of tests prior to morning dose separated by 30 minutes, and then 1 set at 30 minutes, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-morning dose</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Formoterol 12 μg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol fumarate 12 μg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aclidinium 200 μg / formoterol 12 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aclidinium 200 μg / formoterol 6 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aclidinium 200 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aclidinium bromide 200 μg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium 200 μg / formoterol 12 μg</intervention_name>
    <description>Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) twice daily</description>
    <arm_group_label>Aclidinium 200 μg / formoterol 12 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo control twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol 12 μg</intervention_name>
    <description>Formoterol fumarate 12 μg twice daily</description>
    <arm_group_label>Formoterol 12 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium 200 μg</intervention_name>
    <description>Aclidinium bromide 200 μg twice daily</description>
    <arm_group_label>Aclidinium 200 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium 200 μg / Formoterol 6 μg</intervention_name>
    <description>Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) twice daily</description>
    <arm_group_label>Aclidinium 200 μg / formoterol 6 μg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult male or non-pregnant, non-lactating female aged between 40 and 80 years old,
             both inclusive.

          2. Patient with a clinical diagnosis of stable moderate to severe COPD according to the
             GOLD classification

          3. Current, or ex-cigarette smoker with a smoking history of at least 10 pack-years.

          4. Patient whose FEV1 at the Screening Visit measured between 10-15 minutes post
             inhalation of 400 mcg of salbutamol is 30% FEV1 &lt;80% of the predicted normal value
             (i.e., 100 x Post-salbutamol &lt; FEV1/ Predicted FEV1 must be &lt; 80% and ≥ 30%).

          5. Patient whose FEV1/FVC at the Screening Visit measured between 10-15 minutes post
             inhalation of 400 mcg of salbutamol is &lt; 70% (i.e., 100 x Post-salbutamol FEV1 /FVC &lt;
             70%).

          6. Patient who is eligible and able to participate in the trial and who consent to do so
             in writing after the purpose and nature of the investigation have been explained.

          7. Patient whose COPD symptoms and FEV1 values at the time of randomisation are stable
             compared to the Screening Visit, according to the investigator's medical judgment

        Exclusion Criteria:

          1. History or current diagnosis of asthma or exercise-induced bronchospasm.

          2. Clinically significant respiratory conditions at the time of Inform Consent signature

          3. Hospitalisation due to COPD exacerbation within the previous 3 months.

          4. Signs of a COPD exacerbation or respiratory infection (including the upper respiratory
             tract) within the previous 6 weeks.

          5. Patient who has a resting systolic blood pressure ≥ 200 mmHg, a resting diastolic
             blood pressure ≥ 120 mmHg or a resting heart rate ≥ 105 bpm at screening visit.

          6. Clinically significant cardiovascular conditions

          7. Presence of symptomatic prostatic hypertrophy and/or bladder neck obstruction.

          8. Presence of narrow-angle glaucoma.

          9. QTc [calculated according to Bazett's formulae (QTc=QT/RR1/2) above 470 milliseconds
             in the ECG performed at Screening Visit,

         10. Patient who does not maintain regular day/night, waking/sleeping cycles
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Garcia, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Constanta</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iasi</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tg Mures</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Deva</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Romania</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
  </removed_countries>
  <link>
    <url>http://www.almirall.com/webcorp2/cda/ImD_04_02.jsp</url>
    <description>Almirall Corporate Website</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=3971&amp;filename=Synopsis%20m-40464-26-Final.pdf</url>
    <description>CSR Synopsis</description>
  </link>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2010</study_first_submitted>
  <study_first_submitted_qc>March 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2010</study_first_posted>
  <results_first_submitted>September 27, 2016</results_first_submitted>
  <results_first_submitted_qc>September 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 15, 2016</results_first_posted>
  <last_update_submitted>January 5, 2017</last_update_submitted>
  <last_update_submitted_qc>January 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchitis</keyword>
  <keyword>Chronic</keyword>
  <keyword>Emphysema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at a total of 28 sites (4 sites in Czech Republic, 5 sites in Germany, 3 sites in Hungary, 4 sites in Poland and 12 sites in Romania)
The first patient was screened in February 2010 and the last patient visit was in September 2010</recruitment_details>
      <pre_assignment_details>A total of 176 patients were screened of whom 135 were assessed as eligible and were randomized into the study
There were 41 screen failures, the main reason being non-fulfilment of inclusion/exclusion criteria</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1</title>
          <description>FDC 200/6 μg - FDC 200/12 μg - Aclidinium 200 μg - Formoterol 12 μg</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2</title>
          <description>FDC 200/12 - Aclidinium 200 - Formoterol 12 - Placebo</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3</title>
          <description>Aclidinium 200 - Formoterol 12 - Placebo - FDC 200/6</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4</title>
          <description>Formoterol 12 - Placebo - FDC 200/6 - FDC 200/12</description>
        </group>
        <group group_id="P5">
          <title>Sequence 5</title>
          <description>Placebo - FDC 200/6 - FDC 200/12 - Aclidinium 200</description>
        </group>
        <group group_id="P6">
          <title>Sequence 6</title>
          <description>FDC 200/6 - Aclidinium 200 - Placebo - FDC 200/12</description>
        </group>
        <group group_id="P7">
          <title>Sequence 7</title>
          <description>FDC 200/12 - Formoterol 12 - FDC 200/6 - Aclidinium 200</description>
        </group>
        <group group_id="P8">
          <title>Sequence 8</title>
          <description>Aclidinium 200 - Placebo - FDC 200/12 - Formoterol 12</description>
        </group>
        <group group_id="P9">
          <title>Sequence 9</title>
          <description>Formoterol 12 - FDC 200/6 - Aclidinium 200 - Placebo</description>
        </group>
        <group group_id="P10">
          <title>Sequence 10</title>
          <description>Placebo - FDC 200/12 - Formoterol 12 - FDC 200/6</description>
        </group>
        <group group_id="P11">
          <title>Sequence 11</title>
          <description>FDC 200/6 - Formoterol 12 - FDC 200/12 - Placebo</description>
        </group>
        <group group_id="P12">
          <title>Sequence 12</title>
          <description>FDC 200/12 - Placebo - Aclidinium 200 - FDC 200/6</description>
        </group>
        <group group_id="P13">
          <title>Sequence 13</title>
          <description>Aclidinium 200 - FDC 200/6 - Formoterol 12 - FDC 200/12</description>
        </group>
        <group group_id="P14">
          <title>Sequence 14</title>
          <description>Formoterol 12 - FDC 200/12 - Placebo - Aclidinium 200</description>
        </group>
        <group group_id="P15">
          <title>Sequence 15</title>
          <description>Placebo - Aclidinium 200 - FDC 200/6 - Formoterol 12</description>
        </group>
        <group group_id="P16">
          <title>Sequence 16</title>
          <description>FDC 200/6 - Placebo - Formoterol 12 - Aclidinium 200</description>
        </group>
        <group group_id="P17">
          <title>Sequence 17</title>
          <description>FDC 200/12 - FDC 200/6 - Placebo - Formoterol 12</description>
        </group>
        <group group_id="P18">
          <title>Sequence 18</title>
          <description>Aclidinium 200 - FDC 200/12 - FDC 200/6 - Placebo</description>
        </group>
        <group group_id="P19">
          <title>Sequence 19</title>
          <description>Formoterol 12 - Aclidinium 200 - FDC 200/12 - FDC 200/6</description>
        </group>
        <group group_id="P20">
          <title>Sequence 20</title>
          <description>Placebo - Formoterol 12 - Aclidinium 200 - FDC 200/12</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="7"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="7"/>
                <participants group_id="P13" count="7"/>
                <participants group_id="P14" count="7"/>
                <participants group_id="P15" count="7"/>
                <participants group_id="P16" count="7"/>
                <participants group_id="P17" count="7"/>
                <participants group_id="P18" count="7"/>
                <participants group_id="P19" count="7"/>
                <participants group_id="P20" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="7"/>
                <participants group_id="P13" count="7"/>
                <participants group_id="P14" count="7"/>
                <participants group_id="P15" count="7"/>
                <participants group_id="P16" count="7"/>
                <participants group_id="P17" count="7"/>
                <participants group_id="P18" count="7"/>
                <participants group_id="P19" count="7"/>
                <participants group_id="P20" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="7"/>
                <participants group_id="P13" count="7"/>
                <participants group_id="P14" count="7"/>
                <participants group_id="P15" count="7"/>
                <participants group_id="P16" count="7"/>
                <participants group_id="P17" count="7"/>
                <participants group_id="P18" count="7"/>
                <participants group_id="P19" count="7"/>
                <participants group_id="P20" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="7"/>
                <participants group_id="P13" count="7"/>
                <participants group_id="P14" count="7"/>
                <participants group_id="P15" count="7"/>
                <participants group_id="P16" count="7"/>
                <participants group_id="P17" count="7"/>
                <participants group_id="P18" count="7"/>
                <participants group_id="P19" count="6"/>
                <participants group_id="P20" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="1"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="1"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="7"/>
                <participants group_id="P13" count="7"/>
                <participants group_id="P14" count="7"/>
                <participants group_id="P15" count="7"/>
                <participants group_id="P16" count="7"/>
                <participants group_id="P17" count="7"/>
                <participants group_id="P18" count="7"/>
                <participants group_id="P19" count="6"/>
                <participants group_id="P20" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="7"/>
                <participants group_id="P13" count="7"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="7"/>
                <participants group_id="P16" count="7"/>
                <participants group_id="P17" count="7"/>
                <participants group_id="P18" count="7"/>
                <participants group_id="P19" count="6"/>
                <participants group_id="P20" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="7"/>
                <participants group_id="P13" count="7"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="7"/>
                <participants group_id="P16" count="7"/>
                <participants group_id="P17" count="7"/>
                <participants group_id="P18" count="7"/>
                <participants group_id="P19" count="6"/>
                <participants group_id="P20" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="7"/>
                <participants group_id="P13" count="7"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="7"/>
                <participants group_id="P16" count="6"/>
                <participants group_id="P17" count="7"/>
                <participants group_id="P18" count="7"/>
                <participants group_id="P19" count="6"/>
                <participants group_id="P20" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study Population</title>
          <description>All patients randomized into the study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="135"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.4" spread="7.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Normalized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) After Morning Study Drug Administration at Day 14</title>
        <description>FEV1 was measured via spirometry: 2 sets of tests prior to morning dose separated by 30 minutes, and then 1 set at 30 minutes, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-morning dose</description>
        <time_frame>0 and 30 minutes and 1, 2, 3, 4, 6, 8, 10 and 12 hours post-morning dose at Day 14</time_frame>
        <population>Intent to treat (ITT) population: all randomized patients who took at least 1 dose of study drug and had at least 1 baseline and 1 post-baseline assessment of value of FEV1</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo twice daily</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium 200 μg / Formoterol 12 μg</title>
            <description>Aclidinium bromide 200 μg + formoterol fumurate 12 μg fixed dose combination (FDC) twice daily</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium 200 μg / Formoterol 6 μg</title>
            <description>Aclidinium bromide 200 μg + formoterol fumurate 6 μg fixed dose combination (FDC) twice daily</description>
          </group>
          <group group_id="O4">
            <title>Aclidinium 200 μg</title>
            <description>Aclidinium bromide 200 μg twice daily</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 12 μg</title>
            <description>Formoterol fumurate 12 μg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Normalized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) After Morning Study Drug Administration at Day 14</title>
          <description>FEV1 was measured via spirometry: 2 sets of tests prior to morning dose separated by 30 minutes, and then 1 set at 30 minutes, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-morning dose</description>
          <population>Intent to treat (ITT) population: all randomized patients who took at least 1 dose of study drug and had at least 1 baseline and 1 post-baseline assessment of value of FEV1</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.041" spread="0.021"/>
                    <measurement group_id="O2" value="0.180" spread="0.021"/>
                    <measurement group_id="O3" value="0.193" spread="0.021"/>
                    <measurement group_id="O4" value="0.139" spread="0.021"/>
                    <measurement group_id="O5" value="0.100" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment and period as fixed effects, subject as random effect, and baseline values at each period as a covariate</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.221</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.174</ci_lower_limit>
            <ci_upper_limit>0.268</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment and period as fixed effects, subject as random effect, and baseline values at each period as a covariate</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.234</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.186</ci_lower_limit>
            <ci_upper_limit>0.281</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning Pre-dose FEV1 at Day 14</title>
        <description>FEV1 was measured via spirometry: 2 sets of tests prior to morning dose separated by 30 minutes</description>
        <time_frame>Day 14</time_frame>
        <population>Intent to treat (ITT) population: all randomized patients who took at least 1 dose of study drug and had at least 1 baseline and 1 post-baseline assessment of value of FEV1</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo twice daily</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium 200 μg / Formoterol 12 μg</title>
            <description>Aclidinium bromide 200 μg + formoterol fumurate 12 μg fixed dose combination (FDC) twice daily</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium 200 μg / Formoterol 6 μg</title>
            <description>Aclidinium bromide 200 μg + formoterol fumurate 6 μg fixed dose combination (FDC) twice daily</description>
          </group>
          <group group_id="O4">
            <title>Aclidinium 200 μg</title>
            <description>Aclidinium bromide 200 μg twice daily</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 12 μg</title>
            <description>Formoterol fumurate 12 μg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose FEV1 at Day 14</title>
          <description>FEV1 was measured via spirometry: 2 sets of tests prior to morning dose separated by 30 minutes</description>
          <population>Intent to treat (ITT) population: all randomized patients who took at least 1 dose of study drug and had at least 1 baseline and 1 post-baseline assessment of value of FEV1</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.059" spread="0.020"/>
                    <measurement group_id="O2" value="0.042" spread="0.020"/>
                    <measurement group_id="O3" value="0.067" spread="0.020"/>
                    <measurement group_id="O4" value="0.072" spread="0.020"/>
                    <measurement group_id="O5" value="0.027" spread="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning Peak FEV1 at Day 14</title>
        <description>FEV1 was measured via spirometry: 2 sets of tests prior to morning dose separated by 30 minutes, and then 1 set at 30 minutes, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-morning dose</description>
        <time_frame>0 and 30 minutes and 1, 2, 3, 4, 6, 8, 10 and 12 hours post-morning dose at Day 14</time_frame>
        <population>Intent to treat (ITT) population: all randomized patients who took at least 1 dose of study drug and had at least 1 baseline and 1 post-baseline assessment of value of FEV1</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo twice daily</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium 200 μg / Formoterol 12 μg</title>
            <description>Aclidinium bromide 200 μg + formoterol fumurate 12 μg fixed dose combination (FDC) twice daily</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium 200 μg / Formoterol 6 μg</title>
            <description>Aclidinium bromide 200 μg + formoterol fumurate 6 μg fixed dose combination (FDC) twice daily</description>
          </group>
          <group group_id="O4">
            <title>Aclidinium 200 μg</title>
            <description>Aclidinium bromide 200 μg twice daily</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 12 μg</title>
            <description>Formoterol fumurate 12 μg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Peak FEV1 at Day 14</title>
          <description>FEV1 was measured via spirometry: 2 sets of tests prior to morning dose separated by 30 minutes, and then 1 set at 30 minutes, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-morning dose</description>
          <population>Intent to treat (ITT) population: all randomized patients who took at least 1 dose of study drug and had at least 1 baseline and 1 post-baseline assessment of value of FEV1</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.052" spread="0.023"/>
                    <measurement group_id="O2" value="0.335" spread="0.023"/>
                    <measurement group_id="O3" value="0.347" spread="0.023"/>
                    <measurement group_id="O4" value="0.255" spread="0.023"/>
                    <measurement group_id="O5" value="0.255" spread="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 days following last dose of the investigational medicinal product (given over 14±2 days of treatment per period, with 4 treatment periods per patient)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo twice daily</description>
        </group>
        <group group_id="E2">
          <title>Aclidinium 200 μg / Formoterol 12 μg</title>
          <description>Aclidinium bromide 200 μg + formoterol fumurate 12 μg fixed dose combination (FDC) twice daily</description>
        </group>
        <group group_id="E3">
          <title>Aclidinium 200 μg / Formoterol 6 μg</title>
          <description>Aclidinium bromide 200 μg + formoterol fumurate 6 μg fixed dose combination (FDC) twice daily</description>
        </group>
        <group group_id="E4">
          <title>Aclidinium 200 μg</title>
          <description>Aclidinium bromide 200 μg twice daily</description>
        </group>
        <group group_id="E5">
          <title>Formoterol 12 μg</title>
          <description>Formoterol fumurate 12 μg twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v13</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication and/or presentation whether complete or partial, of any part of the data or results of this trial will be subject to revision and written agreement between the investigator and sponsor</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

